Simon G A Brown

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7162519/publications.pdf

Version: 2024-02-01

89 papers	7,010 citations	101543 36 h-index	58581 82 g-index
92 all docs	92 docs citations	92 times ranked	5609 citing authors

#	Article	IF	Citations
1	Clinical features and severity grading of anaphylaxis. Journal of Allergy and Clinical Immunology, 2004, 114, 371-376.	2.9	762
2	Second Symposium on the Definition and Management of Anaphylaxis: Summary Reportâ€"Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium. Annals of Emergency Medicine, 2006, 47, 373-380.	0.6	497
3	2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organization Journal, 2015, 8, 32.	3.5	422
4	Anaphylaxis: Clinical patterns, mediator release, and severity. Journal of Allergy and Clinical Immunology, 2013, 132, 1141-1149.e5.	2.9	220
5	Conservative versus Interventional Treatment for Spontaneous Pneumothorax. New England Journal of Medicine, 2020, 382, 405-415.	27.0	164
6	Determinants of Severe Hypoglycemia Complicating Type 2 Diabetes: The Fremantle Diabetes Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2240-2247.	3.6	148
7	Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis. Current Opinion in Allergy and Clinical Immunology, 2005, 5, 359-364.	2.3	140
8	Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet, The, 2003, 361, 1001-1006.	13.7	129
9	Elevated serum cytokines during human anaphylaxis: Identification of potential mediators of acute allergic reactions. Journal of Allergy and Clinical Immunology, 2009, 124, 786-792.e4.	2.9	129
10	2. Anaphylaxis: diagnosis and management. Medical Journal of Australia, 2006, 185, 283-289.	1.7	128
11	Can serum mast cell tryptase help diagnose anaphylaxis?. EMA - Emergency Medicine Australasia, 2004, 16, 120-124.	1.1	120
12	Immune Response to Snake Envenoming and Treatment with Antivenom; Complement Activation, Cytokine Production and Mast Cell Degranulation. PLoS Neglected Tropical Diseases, 2013, 7, e2326.	3.0	92
13	Comparison of <scp>PIRO</scp>,<scp> SOFA</scp>, and <scp>MEDS</scp> Scores for Predicting Mortality in Emergency Department Patients With Severe Sepsis and Septic Shock. Academic Emergency Medicine, 2014, 21, 1257-1263.	1.8	89
14	Sustained Elevation of Resistin, NGAL and IL-8 Are Associated with Severe Sepsis/Septic Shock in the Emergency Department. PLoS ONE, 2014, 9, e110678.	2.5	83
15	Clinical Effects and Antivenom Dosing in Brown Snake (Pseudonaja spp.) Envenoming â€" Australian Snakebite Project (ASP-14). PLoS ONE, 2012, 7, e53188.	2.5	74
16	The Australian Snakebite Project, 2005â€"2015 (ASPâ€20). Medical Journal of Australia, 2017, 207, 119-125.	1.7	70
17	Prevalence, severity, and natural history of jack jumper ant venom allergy in Tasmania. Journal of Allergy and Clinical Immunology, 2003, 111, 187-192.	2.9	67
18	Snakebite in Australia: a practical approach to diagnosis and treatment. Medical Journal of Australia, 2013, 199, 763-768.	1.7	64

#	Article	IF	Citations
19	The Pathophysiology of Shock in Anaphylaxis. Immunology and Allergy Clinics of North America, 2007, 27, 165-175.	1.9	63
20	Clinical effects of redâ€bellied black snake (Pseudechis porphyriacus) envenoming and correlation with venom concentrations: Australian Snakebite Project (ASPâ€11). Medical Journal of Australia, 2010, 193, 696-700.	1.7	58
21	Characterisation of major peptides in â€˜jack jumperâ€™ ant venom by mass spectrometry. Toxicon, 2004, 43, 173-183.	1.6	57
22	Tiger snake (Notechis spp) envenoming: Australian Snakebite Project (ASPâ€13). Medical Journal of Australia, 2012, 197, 173-177.	1.7	51
23	Efficacy of antivenom against the procoagulant effect of Australian brown snake (Pseudonaja sp.) venom: In vivo and in vitro studies. Toxicon, 2007, 49, 57-67.	1.6	47
24	Enzyme immunoassays in brown snake (Pseudonaja spp.) envenoming: Detecting venom, antivenom and venomâ€“antivenom complexes. Toxicon, 2006, 48, 4-11.	1.6	46
25	Randomized Controlled Trial of Intravenous Antivenom Versus Placebo for Latrodectism: The Second Redback Antivenom Evaluation (RAVE-II) Study. Annals of Emergency Medicine, 2014, 64, 620-628.e2.	0.6	45
26	Fatal anaphylaxis following jack jumper ant sting in southern Tasmania. Medical Journal of Australia, 2001, 175, 644-647.	1.7	44
27	Anaphylaxis: Clinical concepts and research priorities. EMA - Emergency Medicine Australasia, 2006, 18, 155-169.	1.1	44
28	Ultrarush versus semirush initiation of insect venom immunotherapy: AÂrandomized controlled trial. Journal of Allergy and Clinical Immunology, 2012, 130, 162-168.	2.9	44
29	Immediateâ€type hypersensitivity drug reactions. British Journal of Clinical Pharmacology, 2014, 78, 1-13.	2.4	44
30	Proteomic analysis of Myrmecia pilosula (jack jumper) ant venom. Toxicon, 2006, 47, 208-217.	1.6	41
31	Clotting factor replacement and recovery from snake venom-induced consumptive coagulopathy. Intensive Care Medicine, 2009, 35, 1532-1538.	8.2	41
32	Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: A test-negative case control study. Vaccine, 2011, 29, 7320-7325.	3.8	41
33	REstricted Fluid REsuscitation in Sepsis-associated Hypotension (REFRESH): study protocol for a pilot randomised controlled trial. Trials, 2017, 18, 399.	1.6	41
34	Influenza Vaccine Effectiveness against Hospitalisation with Confirmed Influenza in the 2010â€“11 Seasons: A Test-negative Observational Study. PLoS ONE, 2013, 8, e68760.	2.5	40
35	Resistin and NGAL are associated with inflammatory response, endothelial activation and clinical outcomes in sepsis. Inflammation Research, 2017, 66, 611-619.	4.0	40
36	Plasma alkalinization for tricyclic antidepressant toxicity: A systematic review. EMA - Emergency Medicine Australasia, 2001, 13, 204-210.	1.1	37

#	Article	IF	Citations
37	Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock. The Cochrane Library, 2018, 2018, CD006312.	2.8	37
38	2. Anaphylaxis: diagnosis and management. Medical Journal of Australia, 2006, 185, 400-400.	1.7	36
39	H1-antihistamines for the treatment of anaphylaxis with and without shock. The Cochrane Library, 2007, , CD006160.	2.8	36
40	Causes of ant sting anaphylaxis in Australia: the Australian Ant Venom Allergy Study. Medical Journal of Australia, 2011, 195, 69-73.	1.7	36
41	Pilosulins: A review of the structure and mode of action of venom peptides from an Australian ant Myrmecia pilosula. Toxicon, 2015, 98, 54-61.	1.6	36
42	Australian taipan (Oxyuranus spp.) envenoming: clinical effects and potential benefits of early antivenom therapy â€“ Australian Snakebite Project (ASP-25). Clinical Toxicology, 2017, 55, 115-122.	1.9	36
43	Changes in serial laboratory test results in snakebite patients: when can we safely exclude envenoming?. Medical Journal of Australia, 2010, 193, 285-290.	1.7	34
44	FluCAN 2009: initial results from sentinel surveillance for adult influenza and pneumonia in eight Australian hospitals. Medical Journal of Australia, 2011, 194, 169-174.	1.7	32
45	Study protocol for a randomised controlled trial of invasive versus conservative management of primary spontaneous pneumothorax. BMJ Open, 2016, 6, e011826.	1.9	31
46	Death Adder Envenoming Causes Neurotoxicity Not Reversed by Antivenom - Australian Snakebite Project (ASP-16). PLoS Neglected Tropical Diseases, 2012, 6, e1841.	3.0	28
47	Mediators Released During Human Anaphylaxis. Current Allergy and Asthma Reports, 2012, 12, 33-41.	5.3	28
48	Serum mast cell tryptase measurements: Sensitivity and specificity for a diagnosis of anaphylaxis in emergency department patients with shock or hypoxaemia. EMA - Emergency Medicine Australasia, 2018, 30, 366-374.	1.1	28
49	Clinically applicable laboratory end-points for treating snakebite coagulopathy. Pathology, 2006, 38, 568-572.	0.6	27
50	Parenteral antihistamines cause hypotension in anaphylaxis. EMA - Emergency Medicine Australasia, 2013, 25, 92-93.	1.1	27
51	A comparison of serum antivenom concentrations after intravenous and intramuscular administration of redback (widow) spider antivenom. British Journal of Clinical Pharmacology, 2008, 65, 139-143.	2.4	26
52	Envenoming by the roughâ€scaled snake (Tropidechis carinatus): a series of confirmed cases. Medical Journal of Australia, 2009, 191, 183-186.	1.7	25
53	Critical illness in the emergency department: Lessons learnt from the first 12 months of enrolments in the Critical Illness and Shock Study. EMA - Emergency Medicine Australasia, 2012, 24, 31-36.	1.1	24
54	Genomic Responses during Acute Human Anaphylaxis Are Characterized by Upregulation of Innate Inflammatory Gene Networks. PLoS ONE, 2014, 9, e101409.	2.5	22

#	Article	IF	Citations
55	Intracranial haemorrhages associated with venom induced consumption coagulopathy in Australian snakebites (ASP-21). Toxicon, 2015, 102, 8-13.	1.6	21
56	Prevention of anaphylaxis with ant venom immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2003, 3, 511-516.	2.3	19
57	Incidence of serum sickness after the administration of Australian snake antivenom (ASP-22). Clinical Toxicology, 2016, 54, 27-33.	1.9	19
58	Myrmecia pilosula (Jack Jumper) ant venom: Validation of a procedure to standardise an allergy vaccine. Journal of Pharmaceutical and Biomedical Analysis, 2008, 46, 58-65.	2.8	18
59	Near-infrared spectroscopy in the assessment of suspected sepsis in the emergency department. Emergency Medicine Journal, 2015, 32, 404-408.	1.0	18
60	Markers Involved in Innate Immunity and Neutrophil Activation are Elevated during Acute Human Anaphylaxis: Validation of a Microarray Study. Journal of Innate Immunity, 2019, 11, 63-73.	3.8	17
61	Migraine precipitated by adenosine. Medical Journal of Australia, 1995, 162, 389-391.	1.7	16
62	Human anti-snake venom IgG antibodies in a previously bitten snake-handler, but no protection against local envenoming. Toxicon, 2010, 55, 646-649.	1.6	16
63	Modified TIMI risk score cannot be used to identify low-risk chest pain in the emergency department: a multicentre validation study. Emergency Medicine Journal, 2014, 31, 281-285.	1.0	15
64	Snakebite-associated thrombotic microangiopathy: an Australian prospective cohort study [ASP30]. Clinical Toxicology, 2022, 60, 205-213.	1.9	15
65	Towards complete identification of allergens in Jack Jumper (Myrmecia pilosula) ant venom and their clinical relevance: An immunoproteomic approach. Clinical and Experimental Allergy, 2018, 48, 1222-1234.	2.9	13
66	Stability of Myrmecia pilosula (Jack Jumper) Ant venom for use in immunotherapy. Journal of Pharmaceutical and Biomedical Analysis, 2011, 54, 303-310.	2.8	12
67	Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and Severe Hypoglycemia Complicating Type 2 Diabetes: The Fremantle Diabetes Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E696-E700.	3.6	11
68	Using Time-Resolved Fluorescence to Measure Serum Venom-Specific IgE and IgG. PLoS ONE, 2011, 6, e16741.	2.5	9
69	Serial multiple biomarkers in the assessment of suspected acute coronary syndrome: multiple infarct markers in chest pain (MIMIC) study. Emergency Medicine Journal, 2013, 30, 149-154.	1.0	9
70	Ant venom immunotherapy in Australia: the unmet need. Medical Journal of Australia, 2014, 201, 33-34.	1.7	9
71	Distinct inflammatory responses differentiate cerebral infarct from transient ischaemic attack. Journal of Clinical Neuroscience, 2017, 35, 97-103.	1.5	8
72	Influenza epidemiology, vaccine coverage and vaccine effectiveness in sentinel Australian hospitals in 2013: the Influenza Complications Alert Network. Communicable Diseases Intelligence, 2014, 38, E143-9.	0.5	8

#	Article	IF	Citations
73	Parallel infusion of hydrocortisone Â± chlorpheniramine bolus injection to prevent acute adverse reactions to antivenom for snakebites. Medical Journal of Australia, 2004, 180, 428-429.	1.7	7
74	Efficacy of ant venom immunotherapy and whole body extracts. Journal of Allergy and Clinical Immunology, 2005, 116, 464-465.	2.9	7
75	Anaphylaxis to bull dog ant and jumper ant stings around Perth, Western Australia. EMA - Emergency Medicine Australasia, 2006, 18, 15-22.	1.1	7
76	Tiger snake (Notechis spp) envenoming: Australian Snakebite Project (ASPâ€•13). Medical Journal of Australia, 2013, 198, 194-195.	1.7	7
77	Pharmaceutical and preclinical evaluation of Advax adjuvant as a dose-sparing strategy for ant venom immunotherapy. Journal of Pharmaceutical and Biomedical Analysis, 2019, 172, 1-8.	2.8	7
78	Global View on Ant Venom Allergy: from Allergenic Components to Clinical Management. Clinical Reviews in Allergy and Immunology, 2022, 62, 123-144.	6.5	7
79	Route of administration of redback spider bite antivenom: Determining clinician beliefs to facilitate Bayesian analysis of a clinical trial. EMA - Emergency Medicine Australasia, 2007, 19, 458-463.	1.1	6
80	High rate of immediate systemic hypersensitivity reactions to tiger snake antivenom. Medical Journal of Australia, 2006, 184, 419-420.	1.7	5
81	Clinical research is a priority for emergency medicine but how do we make it happen, and do it well?. EMA - Emergency Medicine Australasia, 2014, 26, 14-18.	1.1	4
82	Fluid resuscitation for people with sepsis. BMJ, The, 2014, 349, g4611-g4611.	6.0	4
83	Changes in differential gene expression during a fatal stroke. Journal of Clinical Neuroscience, 2016, 23, 130-134.	1.5	2
84	In reply. Annals of Emergency Medicine, 2015, 65, 124-125.	0.6	1
85	Primary outcome measures. BMJ: British Medical Journal, 2009, 339, b3368-b3368.	2.3	1
86	Cardiac arrhythmia or movement artefact?. EMA - Emergency Medicine Australasia, 2009, 21, 86-87.	1.1	0
87	Myth of tension spontaneous pneumothorax. EMA - Emergency Medicine Australasia, 2012, 24, 117-117.	1.1	0
88	Reply. Journal of Allergy and Clinical Immunology, 2013, 132, 1457.	2.9	0
89	Letter to the Editor. Journal of Intensive Care Medicine, 2014, 29, 53-53.	2.8	0